RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pharmaceutical Industry

A collection of news and information related to Pharmaceutical Industry published by this site and its partners.

Top Pharmaceutical Industry Articles

Displaying items 67-77
  • Uber, Carnegie Mellon partnering on driverless car research

    Uber, Carnegie Mellon partnering on driverless car research
    PITTSBURGH — Ride-sharing service Uber is partnering with Carnegie Mellon University on a Pittsburgh research lab both hope could lead to the development of driverless cars. Carnegie Mellon and its Robotics Institute have been working on...
  • Pfizer to pay $17 billion for Hospira Inc.

    Pfizer to pay $17 billion for Hospira Inc.
    Pfizer Inc. led the deal-making in the interconnected pharmaceuticals industry Thursday, saying it would buy Hospira Inc. for about $17 billion, including debt. Hospira is a leader in the generic injectable-medicine market and is among those at the...
  • Alexion Pharmaceuticals Names New CEO

    Alexion Pharmaceuticals Names New CEO
    Alexion Pharmaceuticals Inc. in Cheshire has named a new chief executive, David L. Hallal, to replace current CEO and company founder Dr. Leonard Bell, effective April 1. Bell will continue to serve as chairman of the board of directors, the company...
  • AbbVie's breakup with Shire torpedoes 4th quarter, 2014 results

    AbbVie's breakup with Shire torpedoes 4th quarter, 2014 results
    AbbVie's fourth-quarter and 2014 earnings were defined by an engagement to Irish drugmaker Shire that quickly crumbled. The North Chicago-based biopharmaceutical spinoff from Abbott Laboratories beat expectations on adjusted figures but took a blow...
  • Baxter's 2014 earnings: 4th quarter beat expectations

    Baxter's 2014 earnings: 4th quarter beat expectations
    Baxter International, the Deerfield-based medical products and pharmaceutical company, reported full year 2014 earnings Thursday as well as fourth-quarter results. The company beat expectations in nearly every category. Here's how the quarter and year...
  • Abbott ends 2014 'with good momentum'

    Abbott ends 2014 'with good momentum'
    Abbott Laboratories, a North Chicago-based pharmaceutical and health care products company, reported full year 2014 earnings on Thursday, as well as fourth-quarter results. Abbott performed well overall, with the year marked by sales and acquisitions....
  • Drugs expensive under plans sold on health exchange, survey finds

    Drugs expensive under plans sold on health exchange, survey finds
    The Affordable Care Act is not so affordable for many Marylanders, according to a new survey. The landmark law that was supposed to make insurance available to hundreds of thousands of people without coverage is costing Marylanders so much more in...
  • FDA issues new requirements to improve defibrillator safety

    FDA issues new requirements to improve defibrillator safety
    The Food and Drug Administration is requiring makers of heart-zapping defibrillators to submit more data on the emergency care devices after years of recalls and manufacturing problems. Regulators say companies must now submit new testing data on...
  • AbbVie's new hepatitis C treatment gets approval in EU

    AbbVie's new hepatitis C treatment gets approval in EU
    Drugmaker AbbVie Inc. said Monday that its new, all-pill hepatitis C combo treatment has been approved for patients in the 28 European Union member countries. The company said the European Commission granted marketing authorization for the combination...
  • Hogan's budget includes some cuts, some status quo for economic development programs

    Hogan's budget includes some cuts, some status quo for economic development programs
    Advocates for programs spending state dollars on stem cell research or investment in technology companies were nervous about what Gov. Larry Hogan's budget would hold for them, given warnings of "strong medicine" to cure fiscal woes. But after Hogan's...
  • Gilead shares plunge after Express Scripts spurns its $1,000 hepatitis C pill

    Gilead shares plunge after Express Scripts spurns its $1,000 hepatitis C pill
    Gilead Sciences Inc., already under fire for the high costs of its hepatitis C drugs, took another hit Monday when the nation's largest manager of pharmacy benefits struck an exclusive deal with a rival drugmaker. Express Scripts Holding Co. said Monday...